Making clinical proteomics 100x more robust and 10x faster

Today at AOHUPO in Singapore – Evosep is pleased to announce a new co-marketing partnership with Cellenion. This partnership will enable researchers to access a complete solution for single-cell proteomics, combining Evosep’s cutting-edge liquid chromatography technology with Cellenion’s advanced single-cell isolation and sample preparation platform.

Single-cell proteomics is a rapidly growing field that has the potential to revolutionize our understanding of cellular heterogeneity and function. However, the challenges of isolating and analyzing individual cells have made it a difficult area of research. With this new partnership, Evosep and Cellenion aim to provide researchers with the tools they need to overcome these challenges and advance the field of single-cell proteomics.

Evosep’s innovative technology allows for high-throughput, reproducible and robust separation of peptides, delivering standardized analytical performance. Cellenion’s unique single-cell isolation and dispensing platforms enable researchers to rapidly and reliably isolate and process single cells prior to downstream assays.

Together with sensitive mass spectrometry acquisition, these solutions offer a complete workflow for single-cell proteomics, from cell isolation to data analysis. By combining Evosep’s and Cellenion’s technologies, researchers can now perform comprehensive proteomic analyses of individual cells with higher accuracy, sensitivity and robustness than ever before.

“We are excited to partner with Cellenion and provide researchers with a complete solution for single-cell proteomics,” said Dr. Nicolai Bache, Head of Applications of Evosep. “Our combined expertise in single-cell isolation, sample preparation and liquid chromatography will enable researchers to unlock new insights into cellular function and disease, ultimately leading to better diagnostics and therapeutics.”

“Cellenion is delighted to partner with Evosep to offer our customers a complete solution for single-cell proteomics,” said Dr. Anjali Seth, Head of Single Cell Proteomics at Cellenion. “Our platforms enable the isolation of single cells with high precision and throughput, and by combining this with Evosep’s liquid chromatography technology, researchers can now perform comprehensive proteomic analysis of individual cells with unprecedented accuracy and sensitivity.”

The partnership between Evosep and Cellenion marks a significant step forward for the field of single-cell proteomics, and both companies look forward to working together to advance this exciting area of research.

About Evosep

Evosep aims to improve quality of life and patient care by radically innovating protein based clinical diagnostics, initially through collaborations with world-leading scientists about developing new technologies and solutions to make sample separation 100 times more robust and 10 times faster than todays’ alternatives. Information about Evosep is available at www.evosep.com.

The Evosep One instrument is for Research Use Only (RUO).

About Cellenion

Cellenion, a BICO company, offers solutions and technologies for controlled cell dispensing with applications in the fields of single cell and single cellular aggregates isolation. Our systems allow high throughput, image-based automated dispensing of single cells and/or cell aggregates onto any substrates of choice. Together with a range of dedicated consumables, the solutions enable miniaturization of sample preparation protocols on the same instrument before downstream analysis. With no dead volumes and outstanding recovery rates, Cellenion’s platforms offer unique capacities for applications including single-cell omics, rare cells, cell line development, drug screening and 3D model development. Cellenion operates from Lyon, France, and its product are sold by SCIENION worldwide. Information about Cellenion is available at www.cellenion.com.

About BICO

BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing. The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.

With 32,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 11,000 publications. Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction the world’s organ shortage and speeding up drug development to create the future of life-saving treatments.

BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com

For further information, please contact:

Evosep:

Christian Ravnsborg, CEO, Evosep

E-mail: [email protected]

Cellenion:

Guilhem Tourniaire, Managing Director

E-mail: [email protected]